Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Celgene’s deal-making skills have come under the microscope of late, but the group finally seems to have struck a good bargain with Acceleron and luspatercept.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Celegene's fortunes linked to partner Acceleron's success in key late-stage trials.